The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
Patient who are electrically cardioverted require 1 month of anticoagulation (blood thinner). Rivaroxaban a Xa-inhibitor has been shown to be non-inferior to Warfarin (Vit K antagonist) the current standard of care in many treatment areas. Rivaroxaban will be compared to Warfarin historical control group studying the safety and efficacy in electrically cardioverted patients.
- Rivaroxaban Drug
Intervention Desc: Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin ARM 1: Kind: Experimental Label: Rivaroxaban Description: Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days ARM 2: Kind: Experimental Label: Warfarin and Enoxaparin Historical Control Description: Warfarin and Enoxaparin weight based historic control
- Warfarin and Enoxaparin Drug
Other Names: Coumadin Intervention Desc: Historical Control ARM 1: Kind: Experimental Label: Warfarin and Enoxaparin Description: Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
- Allocation: Non-Randomized
- Masking: Open Label
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
|Type||Measure||Time Frame||Safety Issue|